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Abstract
The C5 complement protein is a potent inflammatory mediator that has been implicated in the pathogenesis of both
stroke and neurodegenerative disease. Microvascular failure is proposed as a potential mechanism of injury. Along
these lines, this investigation examines the role of C5 in the setting of chronic cerebral hypoperfusion. Following
experimental bilateral carotid artery stenosis, C5 protein deposition increases in the corpus callosum over thirty days
(p<0.05). The time course is temporally consistent with the appearance of white matter injury. Concurrently, systemic
serum C5 levels do not appear to differ between bilateral carotid artery stenosis and sham-operated mice, implicating
a local cerebral process. Following bilateral carotid artery stenosis, C5 deficient mice demonstrate decreased white
matter ischemia in the corpus callosum when compared to C5 sufficient controls (p<0.05). Further, the C5 deficient
mice exhibit fewer reactive astrocytes and microglia (p<0.01). This study reveals that the C5 complement protein
may play a critical role in mediating white matter injury through inflammation in the setting of chronic cerebral
hypoperfusion.
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Introduction
Cognitive impairment and dementia are disabling conditions
that are increasingly common with advancing age. With a
rapidly aging population, illnesses such as Alzheimer’s disease
(AD) and vascular dementia are significant health-care
concerns. Clinical imaging, epidemiology, and
pharmacotherapy studies have established a strong
association between cortical hypoperfusion and cognitive
impairment[1-4]. Experimental and clinical studies have
demonstrated that sustained reductions in cerebral blood flow
result in white matter ischemic injury[5,6]. Inflammatory
upregulation and progressive microvascular failure are critical
mediators of acute stroke and cerebral ischemia[7]. In the
setting of chronic cerebral hypoperfusion (CCH), sustained
inflammation may result in regional perfusion deficits and
deficient flow maintenance to critical white matter tracts.
The complement cascade is a phylogenetically ancient
constituent of the innate immune system[8-10]. Its functions are
mediated through the sequential activation and proteolytic
cleavage of a series of serum proteins. Complement activation
occurs through three distinct pathways, all of which converge to
activate the fifth (C5) complement component. This activation
initiates assembly of the terminal membrane attack complex
(C5b-9) (MAC) on target cell surfaces and generation of small
C5 cleavage fragments such as C5a (9 kDa) known as
anaphylatoxins[11]. The anaphylatoxins affect inflammation
through release of cytokines, upregulation of adhesion
molecules and increase in vascular permeability[12,13]. A
central and critical position in the complement cascade renders
C5 (188 kDa) a potent effector of the inflammatory response.
The objective of this study is to dissect the role of the C5
complement component in the setting of experimental CCH
using an antibody to detect the C5α subunit (125 kDa) of C5
complement[14]. First, the temporal pattern of C5 deposition is
examined. Next the effects of C5 modulation on white matter
injury and cellular reactivity are assessed.
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Materials and Methods
Animals and Microcoils
This study was carried out in strict accordance with the
recommendations in the University of Southern California
Animal Care and Use Committee guidelines. The protocol was
approved by the Committee on the Ethics of Animal
Experiments of the University of Southern California (IACUC
number 11565). All surgery was performed under
intraperitoneal ketamine/ xylazine, and all efforts were made to
minimize suffering. Wild type C57BL/6J, C5 deficient C57BL/
10SnJ 10.D2-Hc° (C5D), and C5 sufficient C57BL/10SnJ
10.D2-Hc1 (C5S) mice were purchased from Jackson
Laboratories. Studies were performed on male mice between
9-11 weeks old (weighing 24-29g) during the 9am-3pm time
period. In an effort to quantify pain, distress, or suffering, we
used a 12 point scoring system (0-3 points/category) that
included body weight change, physical appearance,
unprovoked behavior, and response to external stimuli.
Animals were monitored and scores assigned hourly during the
perioperative period and daily subsequently until 30 days in the
post-operative period. Animals scoring a total of 9 or higher on
this scale (out of 12), or 3 in any of the criteria at 24-72h, were
considered distressed and euthanized with ketamine/ xylazine.
All animals were housed and experimental procedures
performed under USC department of Animal Resource
guidance. Microcoils (inner diameter: 0.18mm) were purchased
from Sawane Spring Co (Sawane, Japan).
Bilateral Carotid Artery Stenosis Procedure
Bilateral Carotid Artery Stenosis (BCAS) procedures were
performed in accordance with prior publications[15,16]. After a
seven day quarantine period, mice were anesthetized with and
placed in the prone position. A Laser Doppler Flowmetry (LDF)
microtip fiber probe was fixed to the skull at 1 mm posterior and
2mm left of the bregma. The mouse was then rotated to the
supine position. Through a midline cervical incision, both
common carotid arteries were exposed and a micro-coil (0.18
mm diameter) was applied to each. Rectal temperature was
maintained between 36.5C° and 37C°. Sham operated animals
underwent the same procedure, except the microcoils were not
placed. CBF values were recorded in the supine position just
prior to surgery, following application of the first microcoil, and
following application of the second microcoil using a Probe
418-1 master probe/ PF 5010 laser Doppler Perfusion
Monitoring Unit (Perimed AB, Sweden). Unless otherwise
stated, mice were humanely euthanized at the prespecified
time points by performing a cardiectomy with saline perfusion
while under anesthesia with ketamine (80 mg/kg IP) and
xylazine (10 mg/kg IP).
C5 Deposition and Timeline Studies
C57 Black 6J mice were used for the C5 deposition and
timeline studies. Mice underwent either BCAS or sham
procedures.
Effects of BCAS on C5 Protein Deposition in the Whole
Brain and Corpus Callosum.  On postoperative day thirty,
BCAS (n=6) and sham (n=6) mice were sacrificed. Whole brain
samples were harvested for three mice in each cohort. Corpus
callosum tissue samples were dissected en bloc for the other
three mice in each cohort. Corpus callosum samples were
homogenized together [Pierce RIPA buffer (Thermo Scientific,
prod #89901) with added protease inhibitor cocktail tablets
(Roche, complete mini)] into a single sample for each cohort
due to the relatively small quantity of tissue obtained from each
animal. Western blot analysis was performed on each sample.
Tissue homogenates were separated by SDS-PAGE and
transferred to PVDF membranes. Membranes were blocked by
5% non-fat dry milk in TBST (Tris buffered saline, 0.1% Tween
20) for 1 hour, followed by incubation in goat anti-C5α (1:200,
Santa Cruz sc-21941) primary antibody overnight at 4°C for
detection of the 125 kDa α chain(C5α) of the complement C5
protein (188 kDa). Membranes were then washed with TBST,
adding a secondary antibody at room temperature for 1 hour:
Donkey anti goat IgG-HRP (1:2000, sc-2020). ECL prime
western blotting detection reagent was used for 5 minutes and
placed under the UVP biospectrum 600 imaging system. C5α
and GAPDH protein levels were measured and relative
densities were calculated.
C5 Time Course Following BCAS in the Whole
Brain.  BCAS mice were sacrificed on postoperative day 1
(n=3), 15 (n=3) and 30 (n=3). Whole brain samples were
harvested. Western blot analysis was performed according to
the above protocol.
Serum C5 levels Following BCAS.  Serum was obtained by
direct cardiac puncture at the time of sacrifice from BCAS (n=9)
and sham (n=9) mice used for the above western blot analysis
(postoperative day 1, 15 and 30, n=3 in each cohort). ELISA
was performed for complement component C5 (ηg C5 protein/
mg total protein) according to the manufacturer’s instructions
(Kamiya, WA, USA).
C5 Modulation Studies
Circle of Willis Anatomy.  To date, BCAS studies have only
been reported on C57 Black 6J mice. To assess for similarity in
configuration of the posterior communicating arteries across
the different murine strains utilized in this study, the circle of
Willis anatomy of the C5D and C5S mice were examined. No
BCAS or sham procedures were performed for this portion of
the study. 4 Mice in each of the three groups (C57 black J6,
C5D and C5S) were anesthetized using intraperitoneal sodium
pentobarbital (50mg/kg). Transcardiac perfusion was
performed with 20ml of heparinized saline injection with 50%
solution of ink at a pressure of 150mm Hg into the left ventricle
until the animal’s tongue, lips and paws turned black. Once the
animal was sacrificed, the brain was fixed in 4% PFA from 3 to
4 days and the brain harvested. The circle of Willis vasculature
was examined using a Nikon stereomicroscope and
photographed. Posterior communicating artery size was
visually inspected across the three groups.
Effects of C5 Deficiency in the Setting of BCAS.  C5D
and C5S mice were used for the C5 modulation experiments.
Mice underwent either BCAS or sham procedures and were
sacrificed on post-operative day 30. Mice were divided at
random into four groups and we aimed for 9-10 mice in each
Cerebral Hypoperfusion in C5 Deficiency
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group. We began with n=12 C5D/ BCAS, n=12 C5D/ sham,
n=11 C5S/ BCAS, n=9 C5S/ sham and ended with the final
group numbers as follows: n=10 C5D/ BCAS, n=10 C5D/
sham, n=9 C5S/ BCAS, n=9 C5S/ sham. On postoperative day
30, the mice were deeply anesthetized with ketamine and
xylazine and perfused transcardially with phosphate buffered
saline (PH 7.4) to clear the vasculature of blood, then with a
fixative containing 4% paraformaldehyde and 0.2% picric acid
in 0.1mol/L phosphate buffer (PH7.4). The brains were excised,
and stored for an additional 24 hours in paraformaldehyde at
4C°, then in 20% sucrose in 0.1mol/L PBS (PH7.4). The
operator was blinded to the strain (C5D/C5S) of the mice and
personnel assessing primary outcome were blinded to both the
strain (C5D/C5S) and the operative procedure (BCAS/ sham).
Effects of C5 Deficiency in the Setting of BCAS: CBF and
Mortality.  CBF values are presented as percent change LDF
from supine baseline value following placement of the two
microcoils. Surgical mortality is defined as death within the first
48 hours after surgery, while postoperative mortality is defined
as death between 48 hours of surgery and planned sacrifice
(30 days).
Primary Outcome: White Matter Injury in the Medial
Corpus Callosum Following BCAS.  Harvested brains were
embedded in paraffin. A section of the brain located from 1 mm
anterior to the bregma to 2 mm posterior to the bregma
(adjusted according to mouse atlas) was then sliced into serial
3µm-thick coronal sections. Klüver-barrera (KB) staining was
performed on the slice located at the bregma. White matter
integrity was evaluated in the medial region of the corpus
callosum according to a previously described four point scale at
400x magnification: normal (grade 0), disarrangement of the
nerve fibers (grade 1), formation of marked vacuoles (grade 2),
and disappearance of myelinated fibers (grade 3)[17]. Number
scores were assigned in the left medial corpus callosum and
right medial corpus callosum and the two values averaged.
Average scores from two independent, blinded observers were
calculated for each mouse. The two observers’ scores were
then averaged for a final score
Immunohistochemical Analysis: Reactive Microglia and
Astrocytes, Complement C5 deposition.  Harvested brains
were embedded in paraffin. A section of the brain located from
1 mm anterior to the bregma to 2 mm posterior to the bregma
(adjusted according to mouse atlas) was then sliced into serial
3µm-thick coronal sections. Immunohistochemistry was
performed on the slice posterior to the slice used for KB
staining according to manufacturer’s instructions. After
immunohistochemistry was performed, slides were
deparaffined, and then hydrated by a series of different
concentration alcohol (from 100% to 70%). Antigen was
retrieved by microwave, dipped in 3% H2O2 for 10 min, and
then blocked with serum.
Slides were incubated overnight with a rabbit anti- glial
fibrillary acidic protein (GFAP) antibody (diluted 1:10 000;
Dako, Denmark), rabbit anti-ionized calcium-binding adapter
molecule 1(IBA1) antibody (1:200; Wako, Japan), or rabbit
complement component C5α (125kDa) antibody (1:50 Santa
Cruz, SC-21941). Subsequently, sections were treated with the
appropriate biotinylated secondary antibody Vectastain Elite
ABC kit (Vector Laboratories, Burlingame, California, USA) and
visualized with diaminobenzidine (DAB). Photos of the
immunostained slices were captured by a LAS AF microscope
(Leica, Germany). The optical density of DAB signal was
analyzed and quantified using NIH Image J software
(rsbweb.nih.gov/ij/). The number of positive GFAP and IBA-1
cells were counted in one high powered field in the left medial
corpus callosum and right medial corpus callosum and the two
values averaged. Likewise, mean density for C5α was
measured in one high powered field in the left medial corpus
callosum and right medial corpus callosum and the two values
averaged. The images were converted to 8 bit and adjusted to
threshold to count the positive cells (GFAP/ IBA-1) Protocols
followed the NIH Image J user guide.
Statistical Analysis
SPSS-18 software was used to analyze results. Data were
presented as mean±SEM (normally distributed) or median and
interquartile range (non-parametric). Two tailed t test and one-
way ANOVA followed by Tukey’s test were used to compare
continuous variables. Kruskal Wallis test with post hoc pairwise
comparisons with Bonferroni adjustment was used to compare
ordinal data.
Results
Effects of BCAS on C5 Protein Deposition in the Whole
Brain and Corpus Callosum
Postoperative day 30 western blot analysis of whole brain
homogenates demonstrated a C5α/ GAPDH ratio of 0.044 ±
0.02 (n=3) for the BCAS cohort and a ratio of 0.014±0.01 (n=3)
for the sham cohort (p<.05). See figure 1a.
Postoperative day 30 western blot analysis of one
homogenate from 3 separate BCAS corpus callosum samples
demonstrated a C5α/ GAPDH ratio of .0258 while analysis of
one homogenate from 3 separate sham corpus callosum
samples demonstrated a C5α/ GAPDH ratio of 0.019. See
figure 1b.
CBF values for the total BCAS cohort (mice utilized for
analysis of whole brain and corpus callosum, above)
demonstrated a CBF change of -26.50 % ± 10.29 (n=6) relative
to baseline while sham operated mice exhibited a -5.33% ±
2.14 change (n=6). See Figure S1.
C5 Time Course Following BCAS in the Whole Brain
Western blot analysis yielded mean C5α/ GAPDH ratios of
0.045 ± 0.001 on day 1 (n=3), 0.028±0.001 on day 15 (n=3),
and 0.08±0.001 on day 30 (n=3). Day 1 and day 30 values
were significantly different (p<0.05). CBF change for the 9
BCAS mice was -38.33% ± 6.37. See figure 2.
Serum C5 levels Following BCAS
Serum Elisa C5 values (ηg/mg total protein) were not
significantly different between BCAS (day 1: 6.20 ± 2.70, n=4;
day 15: 5.40±1.10, n=3; day 30: 2.60±1.10, n=3) and sham
operated animals (day 1: 4.70±3.50, n=4; day 15: 4.20±3.80,
n=3; day 30: 2.90±01.20, n=3) at any time point. See figure 3.
Cerebral Hypoperfusion in C5 Deficiency
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Circle of Willis Anatomy
Posterior communicating arteries (PCOM) were present in all
mice and the Circle of Willis anatomy did not seem to differ
grossly between the C57 black 6J, C5D and C5S strains (n=4
in each group) on visual inspection. See Figure S2.
Effects of C5 Deficiency in the Setting of BCAS: CBF
and Mortality
Mean CBF change in the four cohorts were as follows: C5D
sham: -3.71% ±2.49; C5D BCAS: -15.10% ±5.38; C5S sham:
-1.00% ±1.00; C5S BCAS -13.00% ±4.29. Surgical mortality in
the four cohorts was as follows: C5D sham: 0%; C5D BCAS:
0%; C5S sham 0%; C5S BCAS: 18.2%. One of the animals
from the C5D sham group died due to accidental trauma during
handling. Post-operative mortality in the four cohorts was as
follows: C5D sham: 16.7%; C5D BCAS: 9.1%, C5S sham 0%,
C5S BCAS: 0%. See Table S1. Combined surgical and post-
operative mortality were previously reported by other groups at
15% for the 0.18mm BCAS group and 0% for the sham
operated group[18].
Primary Outcome: White Matter Injury in the Medial
Corpus Callosum Following BCAS
The Kruskal Wallis test demonstrated a significant global
difference in median white matter injury score among the four
groups (C5S BCAS, C5S Sham, C5D BCAS, C5D Sham;
p=0.02). The post hoc pairwise comparisons with Bonferroni
adjustment showed significant differences in median white
matter injury score between C5S BCAS (1.0, IQR:0.75-1.0) and
Figure 1.  C5 deposition by Western blot Analysis. C5α levels in sham and BCAS mice at thirty days in A) whole brains and
B) corpus callosum homogenates.  Bottom: Western Blots. Top: Relative C5α densities represented graphically (mean±SEM).
Error bars are not presented in Figure 1b, as homogenates of three separate corpus callosum samples are combined into a single
sample for each group (due to relatively small amount of tissue obtained from each corpus callosum dissection, n=3 for whole brain,
n=3 for corpus callosum homogenates).
doi: 10.1371/journal.pone.0084802.g001
Figure 2.  C5 deposition timeline by Western blot Analysis. C5α levels in BCAS mice at day 1 (n=3), 15 (n=3), and 30
(n=3).  Bottom: Western Blots. Top: Relative C5α densities represented graphically (mean±SEM).
doi: 10.1371/journal.pone.0084802.g002
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C5S sham mice (0.25, IQR:0-0.5, p<0.05). Further, C5D BCAS
mice (0.375, IQR:0-0.5) demonstrated significantly less white
matter injury than C5S BCAS mice (1.0, IQR:0.75-1.0, p<0.05).
No differences in white matter injury existed between C5D
sham (0.5, IQR:0-0.5) and C5D BCAS mice (0.375, IQR:0-0.5,
p=ns). See figure 4.
Immunohistochemical Analysis: Reactive Microglia and
Astrocytes, Complement C5 deposition
Reactive Microglia: IBA-1.  There were significant
differences in IBA-1 cell count staining between C5S BCAS
(101.50 ± 5.71) and C5S sham mice (51.96 ± 7.33, p<0.01) in
the corpus callosum. Further, C5D BCAS mice (56.41 ±6.43)
demonstrated significantly less IBA-1 staining density than C5S
BCAS mice (101.51 ±5.71, p<0.01). No differences in IBA-1
Figure 3.  Serum C5 levels.  Serum C5 measured by ELISA on day 1 (n=4), 15 (n=3), 30 (n=3) for sham and BCAS mice (mean
±SEM).
doi: 10.1371/journal.pone.0084802.g003
Figure 4.  White matter ischemia.  Kluver-Barrera staining for white matter ischemic changes in the medial corpus callosum in C5
sufficient and C5 deficient mice subjected to sham and BCAS operations. Above: White matter injury scores. Middle line is the
median. The (+) is the mean. The upper and lower lines on the box are the 75% and 25%, respectively. The uppermost and
lowermost bars are minimum and maximum, respectively. Values in the text are expressed as median and interquartile range
Below: Representative coronal sections of the right corpus callosum with high magnification insert (medial corpus callosum). Bars
indicate 50µm. n=10 C5D/ BCAS, n=10 C5D/ sham, n=9 C5S/ BCAS, n=9 C5S/ sham.
doi: 10.1371/journal.pone.0084802.g004
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staining density existed between C5D sham (53.31 ±10.51)
and C5D BCAS mice (56.41 ± 6.43, p=ns). See Figure 5.
Reactive Astrocytes: GFAP
There were significant differences in GFAP cell count
staining between C5S BCAS (109.33 ± 3.85) and C5S sham
mice (66.73 ± 6.41, p<0.01) in the corpus callosum. Further,
C5D BCAS mice (69.91 ± 2.58) demonstrated significantly less
GFAP staining density than C5S BCAS mice (109.33 ± 3.85,
p<0.01). No differences in GFAP staining density existed
between C5D sham (64.77 ± 9.69) and C5D BCAS mice (69.91
± 2.58, p=ns). See Figure 6.
Complement Deposition: C5α
There were significant differences in C5α density staining
between C5S BCAS (44.72 ± 23.60) and C5S sham mice
(25.55 ± 4.59, p=0.05) in the corpus callosum. Neither C5D
BCAS nor sham mice demonstrated discernible C5α
Figure 5.  Reactive Microglia: IBA-1 staining for reactive microglia in the medial corpus callosum in C5 sufficient and C5
deficient mice subjected to sham and BCAS operations.  Above: IBA-1 positive cell counts in each experimental group. Below:
Representative coronal sections of the right corpus callosum with high magnification insert (medial corpus callosum). Bars indicate
50µm. n=10 C5D/ BCAS, n=10 C5D/ sham, n=9 C5S/ BCAS, n=9 C5S/ sham.
doi: 10.1371/journal.pone.0084802.g005
Figure 6.  Reactive Astrocytes: GFAP staining for reactive astrocytes in the medial corpus callosum in C5 sufficient and C5
deficient mice subjected to sham and BCAS operations.  Above: GFAP positive cell counts in each experimental group. Below:
Representative coronal sections of the right corpus callosum with high magnification insert (medial corpus callosum). Bars indicate
50µm. n=10 C5D/ BCAS, n=10 C5D/ sham, n=9 C5S/ BCAS, n=9 C5S/ sham.
doi: 10.1371/journal.pone.0084802.g006
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deposition. See Figure 7. There were also significant
differences in C5α density staining between C5S BCAS
(1099.04 ± 332.60) and C5S sham mice (338.18 ± 76.02,
p<0.04 ) in the cerebral cortex.
Discussion
The pathophysiology of white matter injury following chronic
cerebral ischemia is not well understood. Cerebral
hypoperfusion involves blood- brain barrier breakdown[19,20] ,
matrix metalloproteinase activation[21], glial reactivity[17],
oligodendroglial apoptosis[22] ,and cytokine/ chemokine
upregulation[23]. Evidence suggests that inflammation plays a
critical role. The complement cascade is a potent effector of
inflammation during physiologic stress. Through the broad pro-
inflammatory actions of the anaphylotoxins, complement
upregulation is associated with cellular injury in the setting of
stroke and neurodegenerative disease[24]. Chronic cerebral
hypoperfusion integrates elements of each.
The temporal course and functional significance of various
complement components has been studied extensively in the
setting of cerebral ischemia/ reperfusion injury[25]. Specifically,
evidence suggests that neurons in the CNS generate C5a
following ischemic stress, leading to neuronal apoptosis[26].
Studies have demonstrated ischemic protection in C3 knockout
mice [27] and through pharmacologic inhibition of the C3a and
C5a receptors[28]. C3a receptor modulation of granulocyte
infiltration appears to be reperfusion dependent[29]. Together,
these results suggest an anaphylatoxin mediated inflammatory
mechanism of complement related injury. The complement
cascade also assumes an integral role in the initiation and
progression of neurodegenerative disease. Fibrillar Aβ plaques
with extensive deposition of multiple complement components
are found in brains of AD patients[30-32]. Early complement
proteins (C1q, C4, C3, Factor B) have been localized to both
amyloid plaques and tangles, while MAC has also been
associated with myelin membranes[33]. Prior studies have
demonstrated that C5 inhibition results in decreased Aβ plaque
load and improved neurological function in the APP mouse
model[34].,[32]
The current study examines the function of the C5 protein in
white matter ischemic injury following experimental CCH, and
is the first to explore the role of the complement system in this
disease process. C5 occupies a critical position within the
complement cascade, influencing both cellular lysis through
generation of the membrane attack complex and inflammatory
upregulation via the C5a anaphylotoxin. The data generated
from this study advances the hypothesis that the C5
complement protein, through its pro-inflammatory effects
promotes microvascular failure in susceptible white matter
tracts in the setting of CCH. This microvascular failure may
lead to small vessel ischemic injury.
Complement upregulation engenders a pro-inflammatory
milieu which initiates microvascular failure and resultant
cerebral ischemia[35]. Thrombosis of small blood vessels can
result in white matter ischemic change in the same fashion that
the no-reflow phenomenon in large vessel stroke promotes
recruitment of marginally viable penumbral tissue into the
ischemic core through compression of small capillaries[36,37].
In this study, the pattern of C5 upregulation following
experimental CCH is temporally concordant with the
histopathological damage evidenced at sacrifice on day thirty.
These changes are evident on western blot and
immunohistochemical analysis. Broad C5 upregulation might
suggest a lower susceptibility threshold for white matter, rather
than an anatomically specific regional pathology. This is
consistent with the characteristic pattern of cerebral
hypoperfusion secondary to carotid artery stenosis, which
Figure 7.  C5 deposition: C5α staining in the medial corpus callosum in C5 sufficient and C5 deficient mice subjected to
sham and BCAS operations.  Above: C5α density in each experimental group (arbitrary units). Below: Representative coronal
sections of the right corpus callosum with high magnification insert (medial corpus callosum). Bars indicate 50µm. n=10 C5D/
BCAS, n=10 C5D/ sham, n=9 C5S/ BCAS, n=9 C5S/ sham.
doi: 10.1371/journal.pone.0084802.g007
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typically causes ischemic changes in watershed vascular
territories[38]. Astrocyte and microglial activation within the
corpus callosum suggests an inflammatory process.
Complement related alterations in the neurovascular/
oligovascular units could be the initiating source. Similarity in
serum C5 levels between BCAS and sham operated animals at
all the time points implicates a process endogenous to the
native brain cells, rather than leakage of systemic inflammation
through a compromised blood-brain barrier. The findings
suggest an association, or a plausible role, for local
upregulation of the C5 complement protein. Although the
systemic levels of C5 appear to not be significant in sham
operated and BCAS mice, the samples sizes were low, so we
cannot rule out the possibility that systemic upregulation of C5
could have contributed. However, power analysis for white
matter ischemia suggests that 10 animals are enough to
demonstrate significant change
To date, the CCH model employed in this investigation has
only been validated in C57 black 6J mice. Despite the minimal
genetic divergence between murine C57 black 6 and C57 black
10 strains, gross anatomic observations were performed to
document the presence of small PCOM arteries (similar to C57
black 6) in the C57 black 10 mice prior to the C5 deficiency
experiments. The presence of a large PCOM artery might
render the microcoil application incapable of producing
changes consistent with CCH secondary to collateral blood
flow. Vessel caliber appeared similar between the strains. The
C5D BCAS mice showed significantly less injury than the C5S
BCAS cohort. Consistent with prior publications, the differences
in white matter ischemic change, and number of reactive
astrocytes/ microglia were significant between the C5S sham
and BCAS (essentially wild-type) cohorts[15,16]. However, The
C5D BCAS mice demonstrated no significant white matter
ischemic disease or reactivity of astrocytes/ microglia when
compared to the C5D sham operated animals.
An inherent limitation of the study is the use of genetically
altered mice. It is possible that as a result of congenital C5
deficiency, these mice could evolve an adaptive process that
affects neuroprotection. Assessment of targeted C5 inhibition
would help address this question. Also of note, the C5 mutant
allele was created by a “TA” 2 base pair deletion on the C5 α
complement subunit (125 kDa), resulting in a deficient
phenotype, not a genetic knockout[39,40]. Therefore, C5α
antibody was utilized to quantify C5 deposition in both the
timeline and modulation experiments due to better visualization
and binding of the antibody; direct C5a subunit (9 kDa)
visualization was not readily available. The absence of C5
staining in the C5D sham and BCAS mice serves a suitable
negative control.
Further, this study focuses on the time course of C5
deposition and the histopathology associated with C5
modulation. It will be critical to address the behavioral/
neurocognitive manifestations of these structural changes in
future studies. Although C5 occupies a central position in the
complement cascade and appears to influence white matter
ischemic injury following CCH, the role and contributions of
other, upstream complement proteins remains to be
determined.
Supporting Information
Figure S1.  Representative visual documentation of
cerebral hypoxia. Left: Laser Doppler Flowmetry
measurements (arbitrary units) before surgery, after first
microcoil, and after second microcoils (separated by vertical
lines). Right: Corresponding hypoxyprobe of the coronal
section at the bregma.
(TIF)
Figure S2.  Anatomical assessment of Posterior
Communicating Arteries. A) Wild Type C57BL/6J, B) C5
deficient C57BL/10SnJ 10.D2-HC° and C) C5 sufficient C57BL/
10SnJ 10.D2-Hc1 mice all demonstrate similar size and
morphology of posterior communicating arteries anatomy.
Arrows point to Posterior Communicating Arteries.
(TIF)
Table S1.  Cerebral blood flow and mortality rates in C5
sufficient and C5 deficient mice after sham and BCAS
operations. Mortality rates are expressed as frequencies and
cerebral blood flow values as percentage change from
preoperative value (mean ± SEM).
(TIF)
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